Literature DB >> 168239

IgE antipolymyxin B antibody formation in a T cell-depleted bone marrow transplant patient.

J D Lakin, W R Grace, K W Sell.   

Abstract

The production of IgE-class antibody specific for polymyxin B is documented in an 18-year-old white female acute myelocytic leukemic patient in relapse. The patient was rendered T cell-deficient by total body X-irradiation and antihuman thymocyte globulin for the purpose of bone marrow transplatation. Thereafter, symptoms of nasal congestion, rhinorrhea, and perinasal urtication produced by topical application of a polymyxin solution were noted. Reaginic activity mediated by an IgE antibody against polymyxin is documented by Prausnbitz-Küstner-type passive transfer reactions and by an indirect hemagglutination technique developed for these studies. The occurrence of type I hypersensitivity to this topical antibiotic is rare. It is speculated that pharmaceuticals normally having a low sensitizing potential might demonstrate increased reaginic immunogenicity in a spontaneously or iatrogenically T cell-depleted patient.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 168239     DOI: 10.1016/0091-6749(75)90113-x

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  4 in total

1.  Inhalation of polymyxin B as a bronchial provocation method.

Authors:  J Rozniecki; P Gorski
Journal:  Lung       Date:  1978       Impact factor: 2.584

2.  Suppression of lymphocyte responses by cephalosporins.

Authors:  E A Chaperon; W E Sanders
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

Review 3.  Recent studies on the regulation of IgE antibody synthesis in experimental animals and man.

Authors:  D H Katz
Journal:  Immunology       Date:  1980-09       Impact factor: 7.397

4.  Secondary immunoglobulin responses of BALB/c mice previously stimulated with goat anti-mouse IgD.

Authors:  B R Champion; S Buckham; K Page; H Obray; E D Zanders
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.